Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study

Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study

Jean-Marie Rakic,1 Anita Leys,2 Heidi Brié,3 Kris Denhaerynck,4 Christy Pacheco,4 Stefaan Vancayzeele,3 Christine Hermans,3 Karen MacDonald,4 Ivo Abraham4,5 1Department of Ophthalmology, Centre Hospitalier Universitaire de Liège, Site du Sart Tilman, Liège, Belgium;...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Rakic JM, Leys A, Brié H, Denhaerynck K, Pacheco C, Vancayzeele S, Hermans C, MacDonald K, Abraham I
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2013
Materias:
Ophthalmology
RE1-994
Acceso en línea:https://doaj.org/article/68dbf74850fd47c7805c8811c89e837e
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares